N.V. BOLOTOVA, N.YU. FILINA, K.A. CHEREDNIKOVA

Saratov State Medical University named after V.I. Razumovsky, 137 Bolshaya Sadovaya Str., Saratov, Russian Federation, 410054

Bolotova N.V. — D. Sc. (medicine), Professor, Head of the Department of Pediatric Diseases, Pediatric Endocrinology and Diabetology, e-mail: kafedranv@mail.ru, ORCID ID: 0000-0002-8148-526X

Filina N.Yu. — D. Sc. (medicine), Associate Professor of the Department of Pediatric Diseases, Pediatric Endocrinology and Diabetology, e-mail: natalya-filina@rambler.ru, ORCID ID: 0000-0002-1613-4156

Cherednikova K.A. — Postgraduate Student of the Department of Pediatric Diseases, Pediatric Endocrinology and Diabetology, e-mail: iw.nazarenko2012@yandex.ru, ORCID ID: 0000-0001-8119-0405

 A comparative analysis of the effectiveness of various types of drug therapy for adolescent boys 14,5–15,5 years old with a constitutional growth and pubertal delay (CGIP) was made.

Material and methods. 50 patients diagnosed with CGIP were examined. Indicators of physical and sexual development are clinically and laboratory-evaluated before and after the course of puberty initiating therapy in groups of patients receiving testosterone drugs or anabolic steroids. Results. It is shown that the use of stimulating puberty therapy has a beneficial effect on the start of puberty. A comparative characteristic of the effectiveness of various options for stimulation. The conclusion. The best results of therapy were obtained with the use of low doses of testosterone, which is confirmed by clinical and hormonal parameters that determine the onset of puberty without registering side effects.

Key words: growth inhibition, puberty delay, testosterone, inhibin B.

(For citation: Bolotova N.V., Filina N.Yu., Cherednikova K.A. Comparative characteristics of modern methods of drug therapy of constitutional growth inhibition and puberty. Practical Medicine. 2018)

REFERENCES

1. Dedov I.I., Semicheva T.V., Peterkova V.A. Polovoe razvitie detei: norma i patologiya. – Moscow: Kolor It Studio; 2002. 232 р. (In Russ.)
2. Smirnov V.V., Makazan N.V. Functional latency of sexual development: causes, diagnostics, treatment. Lechaschii Vrach, 2012; no 1, pp. 30 (in Russ.)
3. Pushkina S.A. Metabolizm kostnoi tkani pri zaderzhke rosta u detei. [dissertation]  Izhevsk; 2004. (in Russ.)
4. Ashraf T. Soliman, Vincenzo De Sanctis An approach to constitutional delay of growth and puberty Indian Journal of Endocrinology and Metabolism, 2012, vol. 5, no.16, pp. 698-705.
5. G. Kyle, I. Bosaeus, A. D. De Lorenzo, P. Deurenberg, et al. Bioelectrical impedance analysis — part I: review of principles and methods Clinical Nutrition,  2004. vol. 23, no.5, pp 1226–1243.
6. Raigorodskaya N.Yu. Stanovlenie reproduktivnoi sistemy i prognoz fertil’nosti mal’chikov s vrozhdennoi patologiei polovogo razvitiya. dissertation] Moskva; 2015. (in Russ.)
7. Kasatkina E.P. Zaderzhka rosta u detei: differentsial’naya diagnostika i lechenie. Moscow: IMA-press; 2003, p. 23 (In Russ.)
8. Shandin A.N. Klinicheskie varianty i molekulyarnye osnovy idiopaticheskoi nizkoroslosti u detei. [dissertation] Moscow; 2011(in Russ.)
9. Kuchumova O.V. Faktory riska i kliniko-patogeneticheskaya kharakteristika razlichnykh form nizkoroslosti u detei. [dissertation] Samara; 2008(in Russ.)
10. C. Crowne, S. M. Shalet, W. H. B. Wallace, D. M. Eminson et al. Final height in boys with untreated constitutional delay in growth and puberty. Archives of Disease in Childhood, 1990, no. 65, pp. 1109-1112.
11. Harrington, M.R. Palmert Distinguishing Constitutional Delay of Growth and Puberty from Isolated Hypogonadotropic Hypogonadism: Critical Appraisal of Available Diagnostic Tests J Clin Endocrinol Metab, 2012, vol. 97, no. 9, pp. 3056–3067
12. Rohayem, E. Nieschlag, S. Kliesch, M. Zitzmann Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation between constitutional delay of growth and puberty and hypogonadotropic hypogonadism. Andrology, 2015, no. 3, pp. 882–887.
13. Albanese, G. D. Kewley, A. Long, K. N. Pearl et al. Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate. Archives of Disease in Childhood, 1994, vol. 71, pp. 315-317.